Cited by 437Treatment of Major DepressionTryptophan and brain disordersNerve injury and regeneration

Serum levels of brain-derived neurotrophic factor in major depressive disorder: state–trait issues, clinical features and pharmacological treatment

Open access
Molendijk, M L, Bus, B A A, Spinhoven, Ph, Penninx, B W J H, Kenis, G, Prickaerts, J, Voshaar, RC Oude, Elzinga, B M·2011·Molecular Psychiatry

Abstract

Recent evidence supports 'the neurotrophin hypothesis of depression' in its prediction that brain-derived neurotrophic factor (BDNF) is involved in depression. However, some key questions remain unanswered, including whether abnormalities in BDNF persist beyond the clinical state of depression, whether BDNF levels are related to the clinical features of depression and whether distinct antidepressants affect BDNF levels equally. We addressed these questions and investigated serum BDNF levels in 962 depressed patients, 700 fully remitted persons (≥6 months) and 382 healthy controls. We found serum BDNF levels to be low in antidepressant-free depressed patients relative to controls (P=0.007) and to depressed patients who were treated with an antidepressant (P=0.001). BDNF levels of fully remitted persons (whether unmedicated or treated with an antidepressant) were comparable to those of controls. Analyzing the sample of antidepressant-free depressed patients showed that BDNF levels were unrelated to the core clinical features of depression such as its severity or first versus a recurrent episode. The antidepressant associated upregulation of serum BDNF in depressed patients was confined to selective serotonin reuptake inhibitors (SSRIs) (P=0.003) and St John's wort (P=0.03). Our results suggest that low serum levels of BDNF are a state abnormality that is evident during depression and normalizes during remission. Increases in serum levels of BDNF during antidepressant treatment appear to be confined to some antidepressants and do not parallel clinical characteristics, such as the severity of depressive symptoms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2010.98

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lowered serum concentrations of BDNF are associated with MDD.

    “Nevertheless, lowered serum concentrations of BDNF have often been associated with MDD (Karege et al. 2002, 2005; Sen et al. 2008, Molendijk et al. 2011).”
  • Successful antidepressant treatment is usually associated with an increase in BDNF levels in serum and plasma, whereas treatment failure is associated with a lack of response of plasma BDNF levels.

    “Successful antidepressant treatment is usually associated with an increase in BDNF levels in serum and plasma [65, 66], whereas treatment failure is associated with a lack of response of plasma BDNF levels.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Molendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M.
Affiliations
  • Leiden University (NL)
  • Radboud University Nijmegen (NL)
  • University Medical Center Groningen (NL)
  • Maastricht University (NL)
Corresponding author
Molendijk, M L
Venue
Molecular Psychiatry
Published
2010-09-21
Volume
16
Issue
11
Pages
1088-1095
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2096699969
Cited by
437
References
55
Citations by year
2026: 9 · 2025: 21 · 2024: 26 · 2023: 19 · 2022: 16 · 2021: 40 · 2020: 31 · 2019: 32 · 2018: 28 · 2017: 21 · 2016: 28 · 2015: 30 · 2014: 38 · 2013: 44 · 2012: 29
FWCI
23.00
Type
journal article
Language
en
Open access
Locations
  • Molecular Psychiatry (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • VU Research Portal (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Universiteit Leiden
  • ZonMw
  • Vrije Universiteit Amsterdam
  • Universiteit Maastricht
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.085.353)
  • Rivierduinen
  • GGZ Friesland
  • GGZ Drenthe
  • Leids Universitair Medisch Centrum
  • Universitair Medisch Centrum Groningen
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
brain-derived neurotrophic factor, major depressive disorder, serum BDNF, selective serotonin reuptake inhibitors, Hypericum perforatum, trait versus state, clinical features of depression, depression severity
MeSH terms
Adult, Antidepressive Agents, Tricyclic, Anxiety Disorders, Convalescence, Major Depressive Disorder, Female, Humans, Male, Phytotherapy, Middle Aged, Models, Neurological, Models, Psychological, Plant Extracts, Recurrence, Severity of Illness Index, Biomarkers, Drug Monitoring, Selective Serotonin Reuptake Inhibitors, Brain-Derived Neurotrophic Factor, Hypericum

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review